-
Camostat Mesilate: Protease Assay Workflows
2026-09-16
Camostat Mesilate supports mechanism-focused studies of ENaC regulation, plasmin–TGF-β signaling, and hepatic fibrosis. This guide translates its potency, solubility, and handling profile into practical workflows while separating protease biology from unrelated protein–protein interaction strategies.
-
Palonosetron for Chemotherapy-Induced Nausea
2026-09-16
Ruhlmann and Herrstedt review how palonosetron differs from earlier 5-HT3 receptor antagonists in receptor binding, pharmacokinetics, and prevention of chemotherapy-induced nausea and vomiting. The central practical implication is that palonosetron’s pharmacologic advantages may improve protection against delayed symptoms, but clinical interpretation still depends on treatment phase, combination therapy, and separate nausea and emesis endpoints.
-
Camostat Mesilate: From Protease Biology to Assay Design
2026-09-15
Camostat Mesilate is a trypsin-like protease inhibitor with applications spanning ENaC function, plasmin–TGF-β signaling, and hepatic fibrosis research. This article develops a mechanism-first framework for separating protease perturbation from SARS-CoV-2 protein–protein interface inhibition and selecting interpretable assays.
-
Viperin–nsp8 Disruption of Coronavirus Replication
2026-09-15
A 2026 study identifies a protein-level antiviral mechanism in which viperin binds coronavirus nsp8, interferes with replication-transcription complex assembly, and reduces RNA-dependent RNA polymerase activity. Using porcine deltacoronavirus, the work extends viperin biology beyond ddhCTP-mediated chain termination and highlights conserved viperin–nsp8 recognition as a possible direction for antiviral drug development.
-
Cannabidiol in Orofacial Inflammatory Pain
2026-09-14
This 2026 study shows that cannabidiol (CBD) reduces both sensory pain and pain-related affective deficits through coordinated peripheral and central endocannabinoid mechanisms. Its combined behavioral, molecular, and fiber-photometry approach provides a useful framework for separating inflammatory nociception from anxiety-like, depression-like, and cognitive consequences of chronic pain.
-
Mitomycin C Workflows for Cancer Research
2026-09-14
Build reproducible DNA-damage and apoptosis experiments with Mitomycin C, from solvent handling through TRAIL-sensitization assays. The workflow also shows how to use chromosome-transcription readouts as a complementary stress-response layer rather than over-attributing effects to one pathway.
-
Protease Inhibitor Cocktail for OXPHOS Workflows
2026-09-13
Protect intact signaling and metabolic proteins during cancer-cell and tissue extraction with an EDTA-free, broad-spectrum formulation. This guide translates LRPPRC–Dasatinib OXPHOS research into practical Western blot, Co-IP, pull-down, and kinase-assay workflows without claiming that sample preservation alone reproduces the reported biology.
-
Mithramycin A for Sp1-Linked Assay Design
2026-09-12
Mithramycin A offers a mechanistically informed way to probe G-C-rich transcription in cancer and exploratory cardiac-injury assays. This article connects its DNA-binding pharmacology with the miR-24-3p/Sp1/PI3K findings while separating established evidence from testable hypotheses.
-
Capsaicin Assay Workflows: C6366
2026-09-12
Capsaicin SKU C6366 supports controlled cell-viability, proliferation, cytotoxicity, and pain-signaling studies through documented TRPV1 activity, KDM1A/LSD1 inhibition, solubility, and storage parameters. This scenario-based guide helps researchers select concentrations, prepare stocks, interpret assay shifts, and compare supplier options without conflating receptor pharmacology with cytotoxicity.
-
EdU Imaging Kits (488) for Cell-Cycle Decisions
2026-09-11
EdU Imaging Kits (488) provide a direct readout of S-phase DNA synthesis for cell proliferation research. This article explains how to interpret EdU data in mechanistic studies, using recent NSCLC research to connect assay design with defensible cell-cycle conclusions.
-
I-BET151 (GSK1210151A) Workflow Guide
2026-09-11
I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor for studying BRD2, BRD3, and BRD4-dependent transcription in cell and biochemical assays. This guide explains stock preparation, assay controls, and interpretation boundaries; it is for research use only and should not be treated as clinical, diagnostic, or model-independent efficacy evidence.
-
Degarelix Acetate: Receptor Precision to Formulation
2026-09-10
Degarelix acetate is a potent GnRH receptor antagonist for prostate cancer research and endocrine assays. This guide connects receptor pharmacology with peptide aggregation, showing how NMR-informed formulation control can improve hormone secretion inhibition studies.
-
Cy5 NHS ester(Et): Practical Labeling Guide
2026-09-10
Cy5 NHS ester(Et) (SKU A8769) is an amine-reactive, water-soluble fluorescent dye for covalent tagging of proteins, peptides, and related biomolecules. It supports immediate-use labeling workflows, but ethanol-based preparation and long-term storage of working solutions should be avoided.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody
2026-09-09
HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) provides enzyme-based detection of mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It is suitable for validated immunodetection workflows, but optimal dilution, incubation conditions, cross-reactivity, and assay sensitivity should be established experimentally rather than assumed from the product description.
-
CDK9 inhibitor (A3294): Workflow Guide
2026-09-09
CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for investigating CDK9-linked transcription elongation and HIV-1 propagation inhibition. It is appropriate for focused biochemical and cell-based workflows, but not for pan-CDK studies, unvalidated claims of cellular potency, or long-term storage of prepared solutions.